EF Hutton launched coverage of CytoSorbents (NASDAQ:CTSO) with a “buy” rating and $10 target price. The stock closed at $1.03 on July 26. CytoSorbents’ innovative filter cartridges, CytoSorb, and DrugSorb, stand...
CytoSorbents (NASDAQ:CTSO) has received a research grant from a division of the NIH to test the ability of its existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin from septic porcine plasma, a...
The European Union approved CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass. Rivaroxaban is a...
The FDA granted breakthrough therapy designation to CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of ticagrelor during emergency surgery. Ticagrelor is an antiplatelet drug...